Clinical Trial Update: Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating aerosolized Dornase Alfa for efficacy and safety in COVID-19–induced ARDS has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Dornase alfa (dornase alfa)

Snippet

Sponsor: Fondation Ophtalmologique Adolphe de Rothschild | Conditions: COVID-19, Acute Respiratory Distress Syndrome | Phase 3 | Status: TERMINATED